Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer Via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Jiannong Li,Bin Fang,Fumi Kinose,Yun Bai,Jae-Young Kim,Yian A. Chen,Uwe Rix,John M. Koomen,Eric B. Haura

DOI: https://doi.org/10.1158/1535-7163.22503178.v1

2023-01-01

Abstract:Supplemental methods and legends for supplemental figures S1 to S3 and supplemental tables S1 to S3

What problem does this paper attempt to address?

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528425

2023-01-01

Abstract:PDF file, 64K, Non-small cell lung cancer cell lines.
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.
Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528419.v1

2023-01-01

Abstract:PDF file, 53K, mRNA transcripts significantly different between SCLC and NSCLC cell lines.
Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Humam Kadara,Li Shen,Junya Fujimoto,Pierre Saintigny,Chi-Wan Chow,Wenhua Liu,Zuoming Chu,Melinda Garcia,Mohamed Kabbout,You-Hong Fan,Carmen Behrens,Diane A. Liu,Mao Li,J. Jack Lee,Kathryn A. Gold,Jing Wang,Kevin R. Coombes,Edward S. Kim,Waun Ki Hong,Ignacio I. Wistuba

DOI: https://doi.org/10.1158/1940-6207.22524618.v1

2023-01-01

Abstract:PDF file - 6272K, Sweave report depicting complete codes used for microarray analysis and identification of genes differentially expressed by site and time
Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528440.v1

2023-01-01

Abstract:PDF file, 125K, Western blot of total PARP1.
Supplementary Figures 1 - 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Humam Kadara,Li Shen,Junya Fujimoto,Pierre Saintigny,Chi-Wan Chow,Wenhua Liu,Zuoming Chu,Melinda Garcia,Mohamed Kabbout,You-Hong Fan,Carmen Behrens,Diane A. Liu,Mao Li,J. Jack Lee,Kathryn A. Gold,Jing Wang,Kevin R. Coombes,Edward S. Kim,Waun Ki Hong,Ignacio I. Wistuba

DOI: https://doi.org/10.1158/1940-6207.22524624

2023-01-01

Abstract:PDF file - 125K, Histograms of the p-values for site- and time-dependent differential expression; Site-dependent differential gene expression patterns identified by expression profiling of airways excluding main carinas; Smoothened scatter plot of transformed p-values for site and time effects
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Legends from Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers

Hongyi Zhang,Longchao Liu,Jian Zhang,Jiahui Chen,Jianfeng Ye,Sachet Shukla,Jian Qiao,Xiaowei Zhan,Hao Chen,Catherine J. Wu,Yang-Xin Fu,Bo Li

DOI: https://doi.org/10.1158/1078-0432.22479561.v1

2023-01-01

Abstract:Legends for supplementary figures, tables and datasets.
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

K. Mark Parnell,Jason M. Foulks,Rebecca N. Nix,Adrianne Clifford,Jeremy Bullough,Bin Luo,Anna V. Senina,David Vollmer,Jihua Liu,Virgil McCarthy,Yong Xu,Michael Saunders,Xiaohui Liu,Scott Pearce,Kevin B. Wright,Marc O’Reilly,Michael V. McCullar,Koc-Kan Ho,Steven B. Kanner

DOI: https://doi.org/10.1158/1535-7163.22499760.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 41K, Legends for supplemental figures 1-4
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Li Liu,Xue Bai,Jian Wang,Xiaonan Tang,Dehua Wu,Shasha Du,Xiu-Ju Du,Yao-Wei Zhang,Hai‐Liang Zhu,Yuan Fang,Zhimou Guo,Qiandong Zeng,Xuejun Guo,Zhu Li,Zhong‐Yi Dong

DOI: https://doi.org/10.1158/1078-0432.22471917.v1

2023-01-01

Abstract:Supplementary figure legends
Supplementary Methods, Figure Legends from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Stephen J. Blake,Kimberley Stannard,Jing Liu,Stacey Allen,Michelle C.R. Yong,Deepak Mittal,Amelia Roman Aguilera,John J. Miles,Viviana P. Lutzky,Lucas Ferrari de Andrade,Ludovic Martinet,Marco Colonna,Kazuyoshi Takeda,Florian Kühnel,Engin Gurlevik,Günter Bernhardt,Michele W.L. Teng,Mark J. Smyth

DOI: https://doi.org/10.1158/2159-8290.22530993

2023-01-01

Abstract:Supplementary Methods, Figure Legends
Supporting Figure Legends from Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors

Jie Jiang,Fu Gui,Zhiguo He,Li,Yunzhan Li,Shunying Li,Xinrui Wu,Zhiyong Deng,Xihuan Sun,Xin Huang,Wei Huang,Shang Han,Ting Zhang,Zheng Wang,Bo Jiang,Siyang Song,Hongrui Wang,Lanfen Chen,Dawang Zhou,Qiang Liu,Ruibao Ren,Jianming Zhang,Xin Deng

DOI: https://doi.org/10.1158/0008-5472.22413276.v1

2023-01-01

Abstract:Supplementary figure legends
Supplemental Tables from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Renata Ferrarotto,Ruchitha Goonatilake,Suk Young Yoo,Pan Tong,Uma Giri,Shaohua Peng,John D. Minna,Luc Girard,Yuehong Wang,Liguang Wang,Lerong Li,Lixia Diao,David H. Peng,Don L. Gibbons,Bonnie S. Glisson,John V. Heymach,Jing Wang,Lauren A. Byers,Faye M. Johnson

DOI: https://doi.org/10.1158/1078-0432.22458884.v1

2023-01-01

Abstract:Supplemental Tables and Supplementary Figure Legends
Supplementary Figure Legends 1-4, Methods from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Nicolaos Palaskas,Steven M. Larson,Nikolaus Schultz,Evangelia Komisopoulou,Justin Wong,Dan Rohle,Carl Campos,Nicolas Yannuzzi,Joseph R. Osborne,Irina Linkov,Edward R. Kastenhuber,Richard Taschereau,Seema B. Plaisier,Chris Tran,Adriana Heguy,Hong Wu,Chris Sander,Michael E. Phelps,Cameron Brennan,Elisa Port,Jason T. Huse,Thomas G. Graeber,Ingo K. Mellinghoff

DOI: https://doi.org/10.1158/0008-5472.22388192

2023-01-01

Abstract:Supplementary Figure Legends 1-4, Methods from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Peng,Xiaoyan Qiang,Guoyu Li,Lin Li,Shumao Ni,Qi Yu,Laura Sourd,Elisabetta Marangoni,Chao Hu,Dong Wang,Di Wu,Frank Wu

DOI: https://doi.org/10.1158/1535-7163.22523257.v1

2023-01-01

Abstract:This includes the supplementary methods and supplementary table captions.
Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Pei-Ling Chen,Whijae Roh,Alexandre Reuben,Zachary A. Cooper,Christine N. Spencer,Peter A. Prieto,John P. Miller,Roland L. Bassett,Vancheswaran Gopalakrishnan,Khalida Wani,Mariana Petaccia de Macêdo,Jacob L. Austin-Breneman,Hong Jiang,Qing Chang,Sangeetha M. Reddy,Wei-Shen Chen,Michael T. Tetzlaff,Russell Broaddus,Michael A. Davies,Jeffrey E. Gershenwald,Lauren E. Haydu,Alexander J. Lazar,Sapna P. Patel,Patrick Hwu,Wen‐Jen Hwu,Adi Diab,Isabella C. Glitza,Scott E. Woodman,Luis M. Vence,Ignacio I. Wistuba,Rodabe N. Amaria,Lawrence N. Kwong,Víctor G. Prieto,R. Eric Davis,Wencai Ma,Willem W. Overwijk,Arlene H. Sharpe,Jianhua Hu,P. Andrew Futreal,Jorge Blando,Padmanee Sharma,James P. Allison,Lynda Chin,Jennifer A. Wargo

DOI: https://doi.org/10.1158/2159-8290.22531188.v1

2023-01-01

Abstract:Supplementary Figure Legends
Supplementary Experimental Procedures, Supplementary Figure Legends, and Supplementary Tables 1 through 3 from c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers

Aijun Shen,Lu Wang,Min Huang,Jingya Sun,Yi Chen,Yan-Yan Shen,Xinying Yang,Xin Wang,Jian Ding,Meiyu Geng

DOI: https://doi.org/10.1158/0008-5472.22405355.v1

2023-01-01

Abstract:Supplementary Experimental Procedures and Figure Legends. Supplementary Table 1-Comparison of secreted proteins in the culture medium of EBC-1 and EBC-1/SR cells using L-series 507 antibody array. Supplementary Table 2-Names and significant targets of 42 compounds tested against EBC-1/SR and MKN-45/SR cells as single agents or in combination with SGX-523. Supplementary Table 3-Established patient derived xenograft models (more than 10) for in vivo efficacy studies.
Supplementary Methods, Figure Legends 1-5, Table Legends 1-3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389585.v1

2023-01-01

Abstract:PDF file - 121K

Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer Via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figures 1 - 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Legends from Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Supplementary Methods, Figure Legends from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Supporting Figure Legends from Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors

Supplemental Tables from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Supplementary Figure Legends 1-4, Methods from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer

Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Supplementary Experimental Procedures, Supplementary Figure Legends, and Supplementary Tables 1 through 3 from c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers

Supplementary Methods, Figure Legends 1-5, Table Legends 1-3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Figure Legends 1-4, Methods from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers